Jerini AG
Invalidenstrasse 130
Berlin
10115
Germany
Tel: 49-30-97893-0
Fax: 49-30-97893-105
Website: http://www.jerini.de/
Email: info@jerini.com
32 articles about Jerini AG
-
Jerini AG Reports First Quarter 2009 Financial Results
5/15/2009
-
Jerini AG Receives Request for Transfer of Minority Shareholders' Shares in Jerini AG to Shire Deutschland Investments GmbH
12/16/2008
-
Jerini AG Reports Financial Results for First Nine Months of 2008
11/14/2008
-
Jerini AG To Divest Jerini Ophthalmic, JPT Peptide Technologies GmbH, And Jerini's Pre-Clinical Projects
10/10/2008
-
Jerini AG's Management and Supervisory Boards Recommend That Jerini Shareholders Accept Shire Limited's Takeover Offer
8/25/2008
-
Jerini AG Reports Financial Results for First Half 2008
8/14/2008
-
Shire Limited Announces Holding of 81% in Jerini AG and Publication of Offer Document
8/13/2008
-
Jerini AG Receives European Commission Approval for FIRAZYR(R) (Icatibant) in the Treatment of HAE
7/15/2008
-
Shire Limited to Buy German Biotech Jerini AG for $518 Million
7/3/2008
-
Jerini AG to Submit Complete Response to the FDA for Icatibant in the Treatment of HAE
6/23/2008
-
Jerini AG Hires Bank to Explore Sale
6/3/2008
-
Jerini AG Reports First Quarter 2008 Financial Results
5/15/2008
-
Jerini AG Receives Positive CHMP Opinion Recommending European Approval for Icatibant in the Treatment of HAE; FDA Issues Not Approvable Letter
4/25/2008
-
Jerini AG Reports Financial Results for Fiscal Year 2007
3/27/2008
-
FDA Gives Jerini AG Angioedema Drug Priority Review
12/21/2007
-
Jerini AG Announces Research Collaboration Between Jerini Ophthalmic and University College London Institute of Ophthalmology Investigating New Treatments for AMD
12/7/2007
-
Jerini AG Reports Financial Results for First Nine Months of 2007
11/14/2007
-
Jerini AG Submits New Drug Application for Icatibant in the Treatment of HAE to the FDA and Requests Priority Review
10/29/2007
-
Jerini AG Ophthalmic Treats First Patient in Phase I Trial for Age-related Macular Degeneration
10/9/2007
-
Jerini AG Initiates FDA Submission Process of New Drug Application For Icatibant in the Treatment of HAE
10/8/2007